NMN vs Nicotinamide Riboside (NR): An Evidence-Based Comparison
NMN and NR are the two most-studied NAD+ precursors in longevity research. Both raise NAD+ in humans — but they differ on bioavailability pathways, regulatory status, clinical depth and price. Here is how they actually compare, grounded in the human trial evidence.
Last reviewed July 19, 2026 · Reviewed by the SuppIndex research team (editorial policy) · Educational only — not medical advice.
The 30-second answer
- NAD+ elevation: Comparable in humans (~40–90% at 250–1,000 mg/day). No head-to-head trial has shown either is clearly superior.
- Clinical depth: NR has more, longer human trials and NDI/GRAS status. NMN's human evidence is growing quickly but shallower.
- Regulatory: NR is a recognised dietary ingredient in the US; NMN's US status is contested since 2022. UK/EU treat both as novel foods.
- Verdict: If you want the deepest evidence base and clearest regulatory footing, NR. If you want the newer molecule with rapidly accumulating human data and don't mind regulatory uncertainty, NMN.
Side-by-side comparison
| NMN | Nicotinamide Riboside (NR) | |
|---|---|---|
| Molecule | Nicotinamide mononucleotide (NR + phosphate group) | Nicotinamide riboside (nicotinamide + ribose) |
| Uptake pathway | Slc12a8 transporter (proposed); also dephosphorylated to NR intracellularly | Nucleoside transporters; direct salvage to NMN via NRK1/2 |
| Typical dose | 250–900 mg/day (once daily) | 300–1,000 mg/day (once daily) |
| Whole-blood NAD+ change | ~40–80% at 250–900 mg/day (Yoshino 2021, Yamane 2023) | ~40–90% at 300–1,000 mg/day (Martens 2018, Elhassan 2019) |
| Best-supported outcome | Improved skeletal-muscle insulin sensitivity in prediabetic women (Yoshino 2021) | Reduced systolic BP & arterial stiffness in older adults (Martens 2018) |
| Number of human RCTs | ~15+ (growing rapidly since 2020) | ~25+ across metabolic, neuro, cardiovascular endpoints |
| Safety profile | Well-tolerated up to 900 mg/day; mild nausea, flushing | Well-tolerated up to 2,000 mg/day; mild nausea, headache |
| US regulatory status | Contested — FDA excluded from supplement definition (2022) | NDI-acknowledged & GRAS as Niagen® |
| Branded forms | Uthever®, MIB-626 (drug candidate) | Niagen® (ChromaDex), Tru Niagen® |
| Cost / month | ~$30–70 | ~$40–80 |
Human clinical highlights
Martens 2018 (NR) — 12-week RCT, 1,000 mg/day in 30 healthy middle-aged and older adults. NAD+ rose ~60%; systolic blood pressure fell ~9 mmHg in stage-1 hypertensives with reduced aortic stiffness. First rigorous human demonstration that oral NR safely elevates NAD+.
Yoshino 2021 (NMN) — 10-week RCT, 250 mg/day in 25 postmenopausal prediabetic women. Skeletal-muscle insulin sensitivity improved ~25%; no changes in body composition, blood pressure or lipids.
Neither molecule has produced hard-endpoint outcome data (mortality, incident disease) in humans. The current evidence base supports safe NAD+ elevation with modest, domain-specific downstream signals — not "reverse-aging" claims.
Pick NR if…
- You want the deepest human evidence base
- US regulatory certainty matters to you (Niagen® NDI/GRAS)
- Your primary interest is cardiovascular / arterial-stiffness endpoints
- You prefer a well-characterised branded ingredient supply
Pick NMN if…
- You want the newer molecule with rapidly-accumulating human trials
- Your primary interest is metabolic / insulin-sensitivity endpoints
- You accept ongoing US regulatory uncertainty
- You prefer options such as Uthever® with third-party purity testing
Explore further on SuppIndex
- NMN ingredient page → full evidence score, dosing, safety and linked studies
- Nicotinamide Riboside ingredient page →
- Indexed NAD+ studies →
- NMN regulatory status (GB / EU / US) →
- Ask the Evidence Copilot about NMN or NR →
This article is for educational purposes only and is not medical advice. Consult a qualified healthcare professional before starting any new supplement, particularly if you take prescription medications or have a chronic condition.